Sartorius Stedim Biotech might narrow its full-year sales guidance when it reports second-quarter results in a few weeks, Bernstein's Delphine Le Louet and Susannah Ludwig say in a research note. "We think the company will probably narrow its sales guidance up to the high end from 6-10% to 8-10%," the analysts say. The French lab-tools supplier--which is majority owned by Germany's Sartorius--is doing well across regions, they add. A U.S. slowdown in the first quarter should prove temporary, large pharma customers drive demand for disposable supplies in Europe and Asia, and demand for equipment should show signs of catching up after recent product launches, according to Bernstein. Shares rise 1.8%. (adria.calatayud@wsj.com)
Dow Jones Newswires
Sartorius Stedim Biotech Might Narrow Guidance at Next Results — Market Talk
- Sources
- Dow Jones Newswires
- Markets
- Stocks
- Active symbols
- EURONEXT:DIM
- Language
- English
Sartorius Stedim Biotech might narrow its full-year sales guidance when it reports second-quarter results in a few weeks, Bernstein's Delphine Le Louet and Susannah Ludwig say in a research note. "We think the company will probably narrow its sales guidance up to the high end from 6-10% to 8-10%,"…